MENU
+Compare
SAGE
Stock ticker: NASDAQ
AS OF
Jun 6, 04:59 PM (EDT)
Price
$6.85
Change
+$0.07 (+1.03%)
Capitalization
428.95M

SAGE Sage Therapeutics Forecast, Technical & Fundamental Analysis

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines... Show more

SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for SAGE with price predictions
Jun 05, 2025

SAGE sees its Stochastic Oscillator recovers from oversold territory

On June 05, 2025, the Stochastic Oscillator for SAGE moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SAGE's RSI Indicator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SAGE just turned positive on June 03, 2025. Looking at past instances where SAGE's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SAGE advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

SAGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 30, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SAGE as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

SAGE moved below its 50-day moving average on April 30, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SAGE crossed bearishly below the 50-day moving average on May 05, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SAGE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SAGE entered a downward trend on June 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). SAGE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (8.842) is also within normal values, averaging (263.647).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SAGE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SAGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

SAGE is expected to report earnings to fall 5.70% to -95 cents per share on August 05

Sage Therapeutics SAGE Stock Earnings Reports
Q2'25
Est.
$-0.95
Q1'25
Missed
by $0.02
Q4'24
Missed
by $0.06
Q3'24
Beat
by $0.01
Q2'24
Missed
by $0.06
The last earnings report on April 29 showed earnings per share of -100 cents, missing the estimate of -99 cents. With 772.67K shares outstanding, the current market capitalization sits at 428.95M.
A.I. Advisor
published General Information

General Information

a developer of therapeutics and medicines for central nervous system disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
215 First Street
Phone
+1 617 299-8380
Employees
487
Web
https://www.sagerx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LGOSX26.81N/A
N/A
Lord Abbett Growth Opportunities R4
FIFWX24.15N/A
N/A
Fidelity Advisor Founders Z
PGSLX11.56N/A
N/A
Principal Global Sus Lstd Inf Inst
FDGCX20.41N/A
N/A
Fidelity Advisor Dividend Growth C
ACLAX15.56N/A
N/A
American Century Mid Cap Value A

SAGE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SAGE has been loosely correlated with PHIO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SAGE jumps, then PHIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAGE
1D Price
Change %
SAGE100%
+3.44%
PHIO - SAGE
42%
Loosely correlated
+17.14%
AXON - SAGE
42%
Loosely correlated
+1.08%
HRMY - SAGE
41%
Loosely correlated
-0.79%
VERV - SAGE
36%
Loosely correlated
+8.22%
KZR - SAGE
36%
Loosely correlated
+2.82%
More